In about 4 years, the company has built a strong, diverse generic drug portfolio including limited competition, high volume and difficult to manufacture products that cover a variety of therapeutic areas and dosage forms, including tablets, capsules, oral suspensions and solutions through a combination of in-house development and strategic in-licensing.
We develop our products at our development facility located in Chennai, India as well as through our strategic global network of partners. The company has established a state-of-the-art oral solid dosage manufacturing facility in Cranbury, New Jersey, USA.
We have commercially launched products under the Eywa Label in the U.S. and under the Zista name in UK along with entering into strategic private label opportunities (e.g., unit dose). As a result, our products are available to patients and pharmacies through all channels (e.g., wholesalers, secondary distributors, buying groups etc.).
We are actively extending our product portfolio to China and other growing markets, through partnerships to ensure access to patients and healthcare systems globally.
The company has rapidly progressed from incorporation to first US commercial launch with:
- Investment from Eight Roads Ventures India (the proprietary investment arm of FIL, Fidelity International Limited), US-based F-Prime Capital Partners and Envestor Ventures Limited together with its affiliates (part of the Shriram Group, Chennai, India),
- an Active Product Portfolio of 70+ products
- a Global workforce of 100+ people
- 38 ANDAs (Abbreviated New Drug Application) and MAs (Marketing Authorisations) filed and over 23 approvals received as of December 2019, including in-licensed products.